Drugs / Peanut extract
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03070561 | Jan 2014 → May 2015 | food allergy | Johns Hopkins University | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT03463135 | May 2018 → May 2019 | food allergy | Sanofi | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT05440643 | Sep 2022 → Mar 2026 | food allergy | ALK-Abelló A/S | Completed | No outcome recorded |
| Phase 1/2 | NCT01084174 | Mar 2010 → Jan 2012 | food allergy | Johns Hopkins University | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peanut extract | “Peanut extract” NCT05440643 ↗ |
| Route | Other | “will be placed in one of three areas: the sublingual space, affixed to the buccal mucosa, and in the vestibular space” NCT03070561 ↗ |